Key Takeaways:
Citi raised WuXi AppTec's target price 17% to HK$215 from HK$183 after the contract research firm's H1 results significantly beat expectations.
Citi analysts said demand remains strong across all business segments, with more late-stage CMO projects contributing to the earnings beat. The bank raised its 2026-2028 revenue forecasts by 8% and EPS estimates by 18%, 19%, and 15% respectively, reflecting higher revenue guidance and margin expansion.
WuXi AppTec reported H1 revenue of RMB 28.9 billion, up 38.9% year-over-year, with net profit attributable to shareholders reaching RMB 11.08 billion, up 29.4%. Diluted EPS rose 25.8% to RMB 3.76. The company raised its 2026 revenue guidance to RMB 58.5-60.5 billion from RMB 51.3-53.0 billion, implying 35-39% growth in continuing operations revenue.
The guidance raise reflects management's confidence in sustained demand for Chinese pharmaceutical outsourcing services. Citi's revised forecasts incorporate a 3-5 percentage point currency headwind from USD depreciation. Investors will watch whether the company's legal challenge to its inclusion on the U.S. Department of Defense's 1260H list — with a hearing held July 22 — affects future order flow.
Small-molecule CDMO revenue surged 72.7% to RMB 14.99 billion, while backlog for continuing operations rose 25.2% to RMB 66.43 billion. H1 unfulfilled orders grew about 30%, with new orders up more than 40% year-over-year. Mid-to-late stage pipeline revenue now accounts for over 50% of total revenue, with more than 80% of late-stage and commercial projects originating from internal early-stage pipelines. The chemistry segment, the primary growth driver, generated RMB 24.99 billion in H1 revenue, up 53.3% year-over-year.
Hong Kong-listed shares of WuXi AppTec rose more than 11% on Aug. 5 following the results, while the broader CXO sector rallied. Genscript Bio gained 10%, Asymchem rose 8%, and Pharmaron advanced 7%. The company also raised its 2026 capex guidance to RMB 7.5-8.5 billion from RMB 6.5-7.5 billion to support accelerated global capacity expansion, including early commencement of its new Changzhou facility. An interim dividend of RMB 5.10 per 10 shares was declared.
The broader CXO sector is benefiting from sustained business development activity. China's pharmaceutical outbound licensing deals reached USD 99.7 billion in H1 2026, nearly double the full-year 2024 total of USD 52.2 billion. Zheshang Securities noted that leading CXO companies are gradually returning to a revenue growth range of 15%-30%, with order growth at companies like WuXi AppTec and Pharmaron recovering to pre-pandemic levels.
This article is for informational purposes only and does not constitute investment advice.
